Moderna & Merck’s Personalized mRNA Cancer Immunotherapy Reaches Clinical Milestone
Moderna and Merck have announced five-year follow-up data from the Phase 2b KEYNOTE-942 study of intismeran autogene (mRNA-4157/V940), an individualized mRNA neoantigen therapy, in combination with Keytruda (pembrolizumab) for patients with high-risk melanoma.
The data highlight the potential of personalized mRNA approaches in precision oncology.
Key Points
- Next-gen cancer immunotherapy enabled by personalized mRNA technology
- Long-term follow-up data demonstrating sustained clinical value
- Expansion of mRNA applications into precision oncology
- Broader clinical development across multiple tumor types
Intismeran autogene is designed using each patient’s tumor mutation profile to generate an individualized mRNA therapy targeting neoantigens and activating an immune response.
In the KEYNOTE-942 Phase 2b study, the combination of intismeran autogene and Keytruda demonstrated improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared with Keytruda alone.
The progress highlights how mRNA technology is expanding beyond infectious disease applications into precision oncology approaches based on individual tumor biology.
Developing personalized cancer immunotherapies requires not only scientific expertise, but also integrated capabilities across tumor profiling, biomarker research, translational research, clinical development, regulatory strategy, and other key functions.
Greenstaff Life Sciences will continue to leverage its specialist talent network across TR, CMC, and BD to support innovative drug development through both talent support and execution capability building.
Congratulations to the teams at Moderna and Merck.